Publications by authors named "T Alain"
In 2020, people living with HIV (PLHIV) in France were worried that the COVID-19 health crisis would lead to long-term changes in their HIV care. Using data from the anonymous, online, cross-sectional survey ACOVIH, which was completed by PLHIV between July and September 2020, this study explored factors associated with worry about long-term changes to HIV care after the end of the first lockdown (17 March-11 May 2020). Using multivariate logistic regression, we compared participants who declared they were worried about long-term changes with those who did not, in terms of their demographic, behavioral, and socioeconomic characteristics, as well as their experience of the COVID-19 crisis and access to care.
View Article and Find Full Text PDFArticle Synopsis
- Optimizing oncolytic viruses for cancer treatment involves removing harmful genes and adding new ones to improve their ability to replicate and stimulate immune responses.
- The complex nature of viral genomes and the difficulty of creating modified viruses have slowed progress in developing these therapies.
- Researchers used a novel strategy involving antibiotics, transposon systems, and advanced sequencing to efficiently engineer safer and more effective oncolytic viruses by identifying useful genetic changes.
The 4EHP-mediated translational repression of cGAS impedes the host immune response against DNA viruses.
Proc Natl Acad Sci U S A
November 2024
A critical host response against viral infections entails the activation of innate immune signaling that culminates in the production of antiviral proteins. DNA viruses are sensed by the cytosolic pattern recognition receptor cyclic GMP-AMP synthase (cGAS), which initiates a signaling pathway that results in production of proinflammatory cytokines such as Interferon-β (IFN-β) and activation of the antiviral response. Precise regulation of the antiviral innate immune response is required to avoid deleterious effects of its overactivation.
View Article and Find Full Text PDFArticle Synopsis
- - The study explores the use of an oncolytic reovirus (RC402) administered orally to stimulate antitumor immunity in advanced cancers, showing no major side effects while effectively reducing tumor lesions.
- - The orally delivered reovirus interacts with the immune system, enhancing antibody production, reshaping the gut microbiome, and promoting immune activation, though it doesn't directly infect tumors outside the gastrointestinal tract.
- - Combining oral reovirus treatment with immune checkpoint inhibitors (like αPD-1 and αCTLA-4) significantly enhances tumor regression and establishes lasting immune memory, highlighting its potential as an effective immunotherapy approach in cancer treatment.